The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

Consumer confidence fell 6.7% to 81.9 in September 2026, hitting its lowest level since April 2014, driven by concerns about labor market conditions and Middle East geopolitical tensions. The Federal Reserve hiked interest rates by 25 basis points and hinted at further increases. In response, four defensive stocks from healthcare and consumer staples sectors are recommended: Bausch Health Companies, CareDx, Dole, and The Chefs' Warehouse.

With inflation remaining stubbornly high at 3.4% annually and a 90% probability of a Federal Reserve rate hike expected, the article recommends four defensive healthcare stocks: Amgen, Bausch Health, CareDx, and Centene. CareDx and Centene are expected to deliver over 100% earnings growth this year, while all four stocks have seen improved earnings estimates over the past 60 days.

Rising oil prices amid escalating Middle East tensions between the US and Iran are driving market volatility and inflation concerns. The Federal Reserve is expected to hike interest rates next month. Investors are rotating toward defensive stocks in consumer staples and healthcare sectors.

CareDx stock surged 14.72% after the precision medicine diagnostics company raised its full-year revenue and earnings forecasts. The company reported adjusted net income more than tripled to $20 million ($0.37 per share), significantly exceeding Wall Street estimates of $0.23 per share. Growth was driven by increased demand for non-invasive transplant monitoring tests, favorable reimbursement dynamics, and CMS coverage affirmation for kidney, heart, and lung transplant surveillance testing.

CareDx agreed to sell its Lab Products business to EuroBio Scientific for $170 million in cash, allowing the company to focus on its higher-growth Testing Services and Patient and Digital Solutions segments. The company reported strong preliminary Q1 2026 results with 39% year-over-year revenue growth, with Testing Services up 48% and Patient and Digital Solutions up 33%. CareDx stock surged 28.54% on the announcement.

CareDx CEO John Walter Hanna Jr. sold 19,480 shares on January 21-22, 2026, totaling approximately $412,200 at an average price of $21.16 per share through a pre-planned Rule 10b5-1 trading plan. The sale reduced his direct holdings by 3.16%, leaving him with 597,405 shares. The article notes this shouldn't concern investors, as the company reported strong Q4 2025 preliminary results with $108 million in revenue (25% YoY growth) and expects continued growth in 2026 from its testing solutions.

Johnson Fistel, a law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. for potential breaches of fiduciary duties and violations of federal securities laws. The investigation is related to CareDx's issuance of false and misleading public statements regarding its compliance with healthcare laws and revenue growth, which led to a significant drop in the company's stock price.

The law firm Morris Kandinov is investigating several companies, including CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc., for potential breaches of fiduciary duties and other legal violations on behalf of shareholders.

Morris Kandinov, a national law firm, is investigating potential breaches of fiduciary duties and other legal violations by CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc. Shareholders are encouraged to contact the firm to learn more about their rights.

The liquid biopsy market is experiencing significant growth, driven by advancements in technology and increasing demand for non-invasive diagnostic methods. North America is the largest market, with a 48.11% share in 2023. Key drivers include increased benefits over conventional biopsy, rising cancer incidence, and technological advancements, while high costs and shortage of skilled professionals pose challenges.

This report analyzes the global market for laboratory-developed tests (LDTs), including the impact of new FDA regulations introduced in 2024. It covers the LDT services market and the market for LDT products sold to clinical laboratories, with a focus on key segments like infectious disease and oncology.